Hodgkin Disease: Prediction of Outcome with 67Ga Scintigraphy after One Cycle of Chemotherapy
Dov Front, MD, PhD1,
Rachel Bar-Shalom, MD1,
Maya Mor, MD1,
Nissim Haim, MD2,
Ron Epelbaum, MD2,
Alex Frenkel, DSc1,
Diana Gaitini, MD3,
Gerald M. Kolodny, MD1 and
Ora Israel, MD1
1 Departments of Nuclear Medicine (D.F., R.B.S., M.M., A.F., G.M.K., O.I.)
2 Oncology (N.H., R.E.)
3 Radiology (D.G.), Rambam Medical Center and the Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 35254, Israel.
View larger version (12K):
[in a new window]
|
Figure 1. Failure-free survival curves of patients with HD who had positive and those who had negative 67Ga scintigrams after one cycle of chemotherapy.
|
|
View larger version (14K):
[in a new window]
|
Figure 2. Failure-free survival curves of patients with HD who had positive and those who had negative 67Ga scintigrams at midtreatment (difference between groups is not significant [NS]).
|
|
View larger version (14K):
[in a new window]
|
Figure 3. Failure-free survival curves of patients with HD who had positive and those who had negative CT scans at midtreatment (difference between groups is not significant [NS]).
|
|
Copyright © 1999 by the Radiological Society of North America.
